Hospitalized cancer patients with comorbidities and low lymphocyte counts had poor clinical outcomes to immune checkpoint inhibitors

BACKGROUND: Immune checkpoint inhibitor (ICI) therapy has improved survivals with a favorable toxicity profile in a variety of cancer patients. We hypothesized that hospitalized cancer patients who have acute or chronic comorbidities may have suppressed immune systems and poor clinical outcomes to I...

Descripción completa

Detalles Bibliográficos
Autores principales: Young, Richard Benjamin, Panchal, Hemali, Ma, Weijie, Chen, Shuai, Steele, Aaron, Iannucci, Andrea, Li, Tianhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9515784/
https://www.ncbi.nlm.nih.gov/pubmed/36185315
http://dx.doi.org/10.3389/fonc.2022.980181

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9515784/
https://www.ncbi.nlm.nih.gov/pubmed/36185315
http://dx.doi.org/10.3389/fonc.2022.980181

Ejemplares similares